This inventor holds 1 USPTO granted patent. Top assignee: Sanofi-Aventis. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: **Gunther Schmalz: Innovating Drug Development in Bruhl, Germany**
Introduction
Gunther Schmalz, based in Bruhl, Germany, is an inventive mind contributing to the field of pharmaceutical research. With a focus on the production of mumbaistatin derivatives, his work encompasses significant advancements in drug development.
Latest Patents
Gunther Schmalz holds one notable patent titled "Method for the production of mumbaistatin derivatives." This patent elucidates a process for preparing mumbaistatin derivatives, where the anthraquinone skeleton is synthesized through a Diels-Alder reaction, and the central methylene bridge is constructed via a transition metal-catalyzed reaction. His innovation extends to the intermediates utilized throughout this process.
Career Highlights
Currently, Gunther is associated with Sanofi-Aventis, a global leader in the pharmaceutical industry. His dedication and expertise have made a substantial impact within the company, focusing on innovative techniques in drug production.
Collaborations
Gunther works alongside notable colleagues such as Lothar Schwink and David Sucunza. Their collaboration fosters a rich environment for creativity and progress in their research endeavors.
Conclusion
In summary, Gunther Schmalz's contributions to pharmaceutical innovation through his patent on mumbaistatin derivatives reflect his commitment to advancing drug development. His work at Sanofi-Aventis, with the support of his esteemed colleagues, highlights the importance of collaboration in the realm of scientific research.